-
公开(公告)号：US20240141070A1
公开(公告)日：2024-05-02
申请号：US17769544
申请日：2020-10-16
发明人： Ting XU , Pilin WANG , Kangping GUO , Yuhao JIN , Ting CHEN , Li GAO , Qingqing ZHANG
CPC分类号： C07K16/468 , A61P31/04 , A61P31/20 , A61P35/00 , C12N15/63 , C07K2317/31 , C07K2317/565
摘要： Provided is an isolated antigen-binding protein, wherein the drug is used for the treatment of tumor, and the isolated antigen-binding protein comprises a PD-L1 binding moiety and an OX40 binding moiety, wherein: the OX40 binding moiety is capable of recognizing and/or binding amino acid residues G70 and/or F71 in a human OX40 extracellular domain; and the PD-L1 binding moiety is capable of recognizing and/or binding amino acid residues I54, Y56, E58, Q66 and/or R113 in an N-terminal IgV domain of human PD-L1. Further provided is a use of the isolated antigen-binding protein in preparing a drug, wherein the drug is used for the treatment of tumors.
-
公开(公告)号：US11634492B2
公开(公告)日：2023-04-25
申请号：US17229392
申请日：2021-04-13
发明人： Ting Xu , Kangping Guo , Dong Yang , Pilin Wang , Yuhao Jin , Xiaoxiao Wang
IPC分类号： C07K16/28 , A61K39/395 , A61P35/00 , A61K39/00
摘要： The present disclosure provides a dimer formed by two polypeptide chains, with each of the two polypeptide chains comprising an antibody Fc subunit, wherein the dimer comprises two or more immunoglobulin single variable domains (ISVDs), at least one of the ISVDs is specific for PD-L1, and at least one of the ISVDs is specific for CTLA4.
-
公开(公告)号：US20210070885A1
公开(公告)日：2021-03-11
申请号：US17022545
申请日：2020-09-16
发明人： Ting XU , Tao XU , Xiaoxiao WANG , Qian LI , Minjie PANG , Huimin ZHANG , Li HAN , Qingqing ZHANG
摘要： The present application provides a bispecific antibody or an antibody mixture with common light chains and a preparation method therefor. the present application also provides a nucleic acid molecule encoding the antibody or the mixture, a recombinant vector and a recombinant cell comprising the nucleic acid molecule, as well as a detection and quantitation method for the antibody or the mixture.
-
公开(公告)号：US20230118053A1
公开(公告)日：2023-04-20
申请号：US17914916
申请日：2021-03-26
发明人： Ting XU , Junfang XU , Pilin WANG , Jing YANG , Jiazhu FANG , Lihong YUN , Yanrong DONG
IPC分类号： A61K39/395 , A61K31/566 , A61P35/00 , A61P35/04 , A61K31/519
摘要： The present application provides a medicinal product comprising: an the HER2 inhibitor or a CDK inhibitor, wherein said CDK inhibitor inhibits CDK4 and/or CDK6. The present application also provides an the HER2 inhibitor for the use of treating tumor in combination with a CDK inhibitor, as well as their use in the preparation of a medicament for treating tumor. The combination in present will significantly enhance tumor inhibiting.
-
公开(公告)号：US20230015590A1
公开(公告)日：2023-01-19
申请号：US17782415
申请日：2020-12-03
发明人： Ting XU , Kangping GUO , Junfang XU , Pilin WANG , Yuhao JIN
摘要： The present disclosure provides a use of a dimer in the preparation of a medicament for treating a tumor in a subject in need thereof, and the dimer formed by two polypeptide chains, with each of the two polypeptide chains comprising an antibody Fc subunit, wherein the dimer comprises two or more immunoglobulin single variable domains (ISVDs), at least one of the ISVDs is specific for PD-L1, and at least one of the ISVDs is specific for CTLA4. The present disclosure also provides a method for treating a tumor in a subject in need thereof, wherein the subject is resistant to the therapy of an immune checkpoint inhibitor.
-
公开(公告)号：US20220251207A1
公开(公告)日：2022-08-11
申请号：US17624795
申请日：2020-07-03
发明人： Ting Xu , Kangping Guo , Xiaoxiao Wang , Pilin Wang , Yuhao Jin , Qian Li
摘要： Disclosed are a method for treating a tumor using a CTLA4-binding protein and a use thereof, wherein the CTLA4-binding protein specifically binds to CTLA4 and does not compete with a ligand of CTLA4 for binding to CTLA4. The CTLA4-binding protein described in the present application can effectively inhibit tumor growth.
-
公开(公告)号：US20240307551A1
公开(公告)日：2024-09-19
申请号：US18575293
申请日：2022-07-04
发明人： Ting Xu , Pilin Wang , Kangping Guo , Yonghao Zhao , Jianjian Peng
CPC分类号： A61K47/6849 , A61K47/68037 , A61K47/6873 , A61K47/6889 , A61P35/00
摘要： An antibody-drug conjugate, comprising a bispecific antibody targeting HER2 or an antigen-binding fragment thereof. Also provided are a preparation method for and an application of the antibody-drug conjugate, and a pharmaceutical composition comprising the antibody-drug conjugate. The antibody-drug conjugate can effectively kill tumors.
-
公开(公告)号：US20230151116A1
公开(公告)日：2023-05-18
申请号：US17914969
申请日：2021-03-26
发明人： Ting XU , Junfang XU , Jing YANG , Jiazhu FANG , Pilin WANG , Ting CHEN
CPC分类号： C07K16/32 , A61P35/00 , C07K2317/31
摘要： The present application provides a method of treating tumor, comprising: administrating a dose of 15 mg/kg to 35 mg/kg of a HER2 bispecific antibody, which comprises a first and a second light chain, a first and a second heavy chain, and variable region of the light chain comprises an amino acid sequence as set forth in any one of SEQ ID NO: 1-6.
-
公开(公告)号：US20220017643A1
公开(公告)日：2022-01-20
申请号：US17496240
申请日：2021-10-07
发明人： Ting XU
摘要： The disclosure is directed to a heterodimer molecule, comprising a first polypeptide chain and a second polypeptide chain, and the first polypeptide chain comprises a first CH3 domain of an antibody heavy chain constant region, the second polypeptide chain comprises a second CH3 domain of an antibody heavy chain constant region. Comparing to a corresponding wild-type CH3 domain of a human antibody heavy chain constant region, the first CH3 domain and the second CH3 domain comprise amino acid mutations at specific positions, for example T366+K409+K392 and T366+L368+Y407+D399+F405, respectively.
-
公开(公告)号：US20210246210A1
公开(公告)日：2021-08-12
申请号：US17229392
申请日：2021-04-13
发明人： Ting Xu , Kangping Guo , Dong Yang , Pilin Wang , Yuhao Jin , Xiaoxiao Wang
IPC分类号： C07K16/28
摘要： The present disclosure provides a dimer formed by two polypeptide chains, with each of the two polypeptide chains comprising an antibody Fc subunit, wherein the dimer comprises two or more immunoglobulin single variable domains (ISVDs), at least one of the ISVDs is specific for PD-L1, and at least one of the ISVDs is specific for CTLA4.
-
-
-
-
-
-
-
-
-
搜索结果
16 条记录 (耗时 0.02 秒)
